Henry Schein currently has a broad portfolio with over $3bn in corporate and owned brand products and services.

Edwards cited broader TAVR treatment populations and ongoing evidence generation as key growth drivers for the new year.

Zimmer Biomet CEO Ivan Tornos has outlined plans for the largest direct to consumer (DTC) campaign in the company’s history ...

During Danaher’s company presentation at this year's J.P. Morgan Healthcare conference in San Francisco, the company ...

GE HealthCare CEO Peter Arduini has highlighted the company’s disciplined approach to M&A in order to “fill gaps and add tuck ...

At its J.P. Morgan Conference 2026 presentation, Qiagen NV alluded to positive full-year results for 2025 and expressed that ...

Clinical expectations in minimally invasive interventions is rising, making collaboration in the medical value chain ...

GE HealthCare’s focus is on connecting equipment, software, and consumables into care pathways, and simplifying its operating ...

Dexcom’s new CEO is eyeing growth in the international market as a key strategy for 2026, fresh off the back of the company ...

Waters Corporation is repositioning its growth profile through the acquisition of Becton Dickinson’s (BD) biosciences and ...

At the ongoing J.P. Morgan Healthcare Conference, Inspire Medical Systems boasted a five-year revenue set to grow at a CAGR ...

Medtronic has outlined both its current market position and ambitious future at the ongoing J.P. Morgan Healthcare Conference ...